Niagen Bioscience, Inc. (NAGE) Tops Q3 EPS by 3c, offers outlook

Niagen Bioscience, Inc. (NASDAQ: NAGE) reported Q3 EPS of $0.05, $0.03 better than the analyst estimate of $0.02. Revenue for the quarter came in at $34 million versus the consensus estimate of $30.83 million.

2025 Full Year Outlook

For the full year, the Company reiterated its recently revised top-line guidance of 25% to 30% year-over-year net sales growth (up from 22% to 27% previously), reflecting continued E-Commerce momentum and new B2B partnerships. Gross margin is expected to improve year-over-year from 61.8% in 2024, driven by supply chain optimization, cost savings initiatives, and the benefit from lower-cost inventory sales. Sales and marketing expenses are projected to increase in absolute dollars compared to $29.5 million in 2024, but decrease as a percentage of net sales compared to 29.6% in 2024, reflecting targeted brand investment and greater marketing efficiency.

The Company is revising its outlook for both research and development, and general and administrative expenses. Research and development expenses are now expected to decrease as a percentage of net sales (previously expected to remain stable) compared to 6.0% in 2024, while continuing to increase in absolute dollars, consistent with prior expectations, and driven by project timing and study progress. General and administrative expenses are now expected to increase to approximately $8.0 to $9.0 million (previously $7.0 to $8.0 million) driven by higher share-based compensation, continued investments to support business growth, and the absence of a $3.5 million royalty expense reversal that occurred in 2024.

For earnings history and earnings-related data on Niagen Bioscience, Inc. (NAGE) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c